All In Biotech

Drug Trial Radar · NCT02817841

E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study

A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone

Last checked: Nov 19, 2026Latest source record: Feb 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,148

Actual

Start

Aug 30, 2016

Primary completion

Oct 16, 2018

Study completion Nov 16, 2018

Sponsor

Lead sponsor
EstetraIndustry
Sponsor type
Industry
Collaborators
PRA Health Sciences
First posted
Jun 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 16 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 16 to 50 years.

Conditions

  • Contraception

Interventions

  • 15 mg E4/3 mg DRSPDrug

    15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of On-treatment Pregnancies (With + 7-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 16 to 35 Years, Inclusive, at the Time of ScreeningTime frame: Up to 12 months (13 cycles with 1 cycle = 28 days)

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Thomas Jefferson University Obstetrics and Gynecology

    Philadelphia, Pennsylvania

  • Clinique de Santé des Femmes

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.